Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model

Cell Metab. 2016 Mar 8;23(3):541-6. doi: 10.1016/j.cmet.2016.01.009. Epub 2016 Feb 11.


Incretin mimetics are frequently used in the treatment of type 2 diabetes because they potentiate β cell response to glucose. Clinical evidence showing short-term benefits of such therapeutics (e.g., liraglutide) is abundant; however, there have been several recent reports of unexpected complications in association with incretin mimetic therapy. Importantly, clinical evidence on the potential effects of such agents on the β cell and islet function during long-term, multiyear use remains lacking. We now show that prolonged daily liraglutide treatment of >200 days in humanized mice, transplanted with human pancreatic islets in the anterior chamber of the eye, is associated with compromised release of human insulin and deranged overall glucose homeostasis. These findings raise concern about the chronic potentiation of β cell function through incretin mimetic therapy in diabetes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy*
  • Drug Evaluation, Preclinical
  • Eye / pathology
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / physiology*
  • Islets of Langerhans Transplantation
  • Liraglutide / pharmacology*
  • Mice


  • Blood Glucose
  • Hypoglycemic Agents
  • Liraglutide